IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.60) per share. This is a 98.1 percent increase over losses of $(31.53) per share from the same period last year.
Barclays Maintains Overweight on Meta Platforms, Raises Price Target to $260
Barclays analyst Ross Sandler maintains Meta Platforms (NASDAQ:META) with a Overweight and raises the price target from $165 to $260.
